Clinical Trials Browser

Interventional × Hepatitis C × Sorafenib × Clear all

NCT04710641 2025-03-06

OUTREACH2

Phase 2 Completed

Gastrointestinal

Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular

NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 1 Completed

Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms